The Drug Enforcement Administration (DEA) is preparing to launch a dedicated online portal for state-licensed medical cannabis cultivators, manufacturers, testing laboratories, and distributors to complete their Schedule III cannabis registration. This development, anticipated in the “coming weeks,” follows the opening of a similar registration process for medical cannabis dispensaries on April 29, 2026.
The DEA’s Diversion Control Division previously initiated a registration window for state-sanctioned medical cannabis dispensaries, allowing those who applied by June 26, 2026, to receive an expedited review within six months. This move followed Acting Attorney General Todd Blanche’s signed order (AG Order No. 6754-2026) to reclassify medical cannabis in the U.S. under Schedule III, aligning with the United Nations Single Convention on Narcotic Drugs.
Initially, it was unclear whether other license types, such as manufacturers, would use the standard DEA Form 225 or if a separate portal would be created. The DEA has since clarified that while Form 225 can be used, an updated, specific application for non-dispensary businesses is forthcoming.
The application fees for Schedule III cannabis registration vary by business type. According to the DEA’s Form 225 tab:
For medical cannabis dispensaries, the nonrefundable application fee is $794. The DEA currently accepts bank-to-bank transfers via automated clearing house (ACH) or PayPal, with additional payment forms expected soon.
The registration application includes questions that require careful consideration from applicants. Specifically, sections on “liability” and “activity” inquire:
Answering “yes” to these questions could indicate prior engagement in federally illegal activities, which carries potential penalties including imprisonment and fines for providing false information to a federal agency.
The move to Schedule III offers several operational and financial advantages for registered medical cannabis businesses. A primary benefit is the opportunity to deduct ordinary business expenses, which Section 280E of the Internal Revenue Code currently disallows for entities dealing with Schedule I and II substances. This tax relief could significantly impact profitability for compliant operators.
Beyond tax implications, Schedule III compliance could open avenues for:
Law firm Foley Hoag noted that a first-mover advantage in registration could encompass these federal protections. The nonpartisan Congress Research Service (CRS) stated in an April 30 legal sidebar that “All entities that handle covered marijuana products, other than end users, will need to register with DEA in order to do so lawfully,” reinforcing the necessity of this registration for operators.
While the Schedule III listing loosens the control status of medical cannabis, it does not legalize it at the federal level. For adult-use cannabis businesses, an expedited administrative hearing is scheduled from June 29 through July 15 to debate the merits of a proposed rule to reclassify all cannabis under Schedule III.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
Based in Australia, we publish industrial hemp and cannabis news, research and industry reports from around the world. Learn more about Hemp Gazette.
© Hemp Gazette